Back to top

Canaccord Genuity Sticks to Their Buy Rating for Apogee Therapeutics (APGE)

In a report released today, Edward Nash from Canaccord Genuity maintained a Buy rating on Apogee Therapeutics, with a price target of $89.00. The c...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Apogee Therapeutics Inc. (APGE)